口服阿奇霉素治疗中重度睑板腺功能障碍的临床疗效

doi:10.3760/cma.j.issn.1674-845X.2019.07.010

摘要
图/表
参考文献
相关文章 (15)

全文: PDF 5893KB HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察分析口服阿奇霉素治疗中重度睑板腺功能障碍（MGD）的临床疗效以及用药后睑板腺结构功能的改变。方法前瞻性临床研究。选取2016年4月至2017年1月就诊于福建医科大学附属第二医院眼科门诊,经眼表综合分析仪检查及裂隙灯显微镜检查诊断为中重度MGD的患者49例（98眼）,分为观察组26例和对照组23例。观察组予人工泪液滴眼,并口服阿奇霉素500 mg每天1次,共3 d,然后停药7 d,10 d为1个治疗周期,共治疗3个周期。对照组仅接受人工泪液滴眼治疗。所有患者首诊及每次随诊均进行改良睑板腺压榨,并配合眼睑热敷及睑缘清洁。观察并比较2组患者治疗前及接受治疗1个月时的国际眼表疾病指数（OSDI）、首次泪膜破裂时间（NIF-BUT）、平均泪膜破裂时间（NIAvg-BUT）、泪河高度（TMH）、眼红分析（R-scan）、睑板腺丢失率、睑板腺开口评分、睑脂质量评分、睑脂排出能力评分、角膜荧光素钠染色（FL）、泪液分泌试验（SⅠT）等指标的变化。组间数据比较采用独立样本t检验和Mann-Whitney U检验,组内数据比较采用配对t检验和Wilcoxon配对秩和检验。结果对照组治疗后睑板腺开口评分（Z=-3.093）、睑脂质量评分（Z=-2.501）、睑脂排出能力评分（Z=-3.175）、FL（Z=-2.602）较治疗前改善,差异均有统计学意义（P<0.05）,余指标差异均无统计学意义。观察组治疗后OSDI（t=6.174）、睑板腺丢失率（t=2.402）、睑板腺开口评分（Z=-5.192）、睑脂质量评分（Z=-5.073）、睑脂排出能力评分（Z=-4.807）、FL（Z=-3.587）较治疗前改善,差异均有统计学意义（P<0.05）,余指标差异均无统计学意义。2组治疗后OSDI（t=-3.778）、NIAvg-BUT（Z=-2.043）、睑板腺丢失率（t=-2.123）、睑板腺开口评分（Z=-6.318）、睑脂质量评分（Z=-5.852）、睑脂排出能力评分（Z=-3.951）、SⅠT（Z=-2.462）差异均有统计学意义（P<0.05）,且观察组改善更明显,余指标差异均无统计学意义。结论口服阿奇霉素联合人工泪液滴眼可用于治疗中重度MGD,能改善MGD患者眼部的主观症状和体征,并改善睑板腺功能。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王红娟
	高莹莹
	李秀兰

关键词 ：睑板腺功能障碍, 阿奇霉素, 临床疗效

Abstract：Objective: To observe the clinical efficacy of oral azithromycin in patients with moderate to severe meibomian gland dysfunction (MGD), and the structural changes in meibomian glands. Methods: This was a prospective clinical study. Forty-nine patients (98 eyes) who had moderate to severe MGD were recruited in the Second Affiliated Hospital, Fujian Medical University, from April 2016 to January 2017. All patients underwent comprehensive ocular surface examination and slit lamp examination and were divided into two groups: 26 patients in the observation group and 23 patients in the control group. The observation group was given artificial tears and oral azithromycin 500 mg once daily for 3 days, then stopped for 7 days. There were 10 days in a treatment cycle with a total of three cycles for the treatment.The control group received only artificial tear treatment. All patients underwent modified meibomian gland compression during the first visit and for each follow-up, all of which were combined with eyelid hot compress and blepharospasm cleaning. Then an ocular check-up was performed, including the following aspects: Ocular surface disease index (OSDI), noninvasive first break-up time (NIF-BUT), noninvasive average break-up time (NIAvg-BUT), tear meniscus height (TMH), R-scan, loss rate of the meibomian gland, assessment of meibomian gland orifices, meibum quality score, meibum expression score, fluorescein stain test (FL), and Schirmer Ⅰ test (SⅠT) between pre-therapy and post-treatment. Data were analyzed by an independent samples t test, Mann-Whitney U test, paired t test and Wilcoxon paired rank sum test. Results: After treatment, the assessment of meibomian gland orifices (Z=-3.093), meibum quality score (Z=-2.501), meibum expression score (Z=-3.175) as well as FL (Z=-2.602) of the control group were improved compared with those before treatment, with statistically significant differences (P<0.05). However, there were no statistically significant differences in other indexes in the control group. After treatment, the OSDI (t=6.174), loss rate of the meibomian gland (t=2.402), assessment of meibomian gland orifices (Z=-5.192), meibum quality score (Z=-5.073), meibum expression score (Z=-4.807), and FL (Z=-3.587) of the observation group were improved compared with those before treatment, with statistically significant differences (P<0.05). There were no statistically significant differences in other indexes in the observation group. Statistically significant differences were observed in OSDI (t=-3.778), NIAvg-BUT (Z=-2.043), loss rate of the meibomian gland (t=-2.123), assessment of meibomian gland orifices (Z=-6.318), meibum quality score (Z=-5.852), meibum expression score (Z=-3.951) and SⅠT (Z=-2.462) between the two groups after treatment (P<0.05) and the observation group improved more obviously, but no statistically significant differences in other indexes after treatment. Conclusions: Oral azithromycin can be used to treat patients with moderate to severe MGD, relieve symptoms and partially regain the function of the meibomian gland.

Key words： meibomian gland dysfunction azithromycin clinical efficacy

收稿日期: 2019-01-07

基金资助:福建省医学创新课题项目（2017-CXB-8）

通讯作者: 高莹莹（ORCID：0000-0002-6869-3013）,Email：gaoyingying1968@163.com

作者简介: 王红娟（ORCID：0000-0001-7785-6876）,Email：506490239@qq.com

引用本文:

王红娟, 高莹莹, 李秀兰. 口服阿奇霉素治疗中重度睑板腺功能障碍的临床疗效[J]. 中华眼视光学与视觉科学杂志, 2019, 21(7): 540-548. Hongjuan Wang, Yingying Gao, Xiulan Li. Oral Azithromycin for the Treatment of Moderate to Severe Meibomian Gland Dysfunction. Chinese Journal of Optometry Ophthalmology and Visual science, 2019, 21(7): 540-548. DOI: 10.3760/cma.j.issn.1674-845X.2019.07.010

链接本文:

https://www.cjoovs.com/CN/10.3760/cma.j.issn.1674-845X.2019.07.010 或 https://www.cjoovs.com/CN/Y2019/V21/I7/540

[1]	Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: Report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci, 2011, 52(4): 1930-1937. DOI: 10.1167/iovs.10-6997b.
[2]	Svanström H, Pasternak B, Hviid A.Use of azithromycin and death from cardiovascular causes. N Engl J Med, 2013, 368(18): 1704-1712. DOI: 10.1056/NEJMoa1300799.
[3]	Yildiz E, Yenerel NM, Turan-Yardimci A, et al.Comparison of the clinical efficacy of topical and systemic azithromycin treatment for posterior blepharitis. J Ocul Pharmacol Ther, 2018, 34(4): 365-372. DOI: 10.1089/jop.2017.0095.
[4]	Balci O, Gulkilik G.Assessment of efficacy of topical azithromycin 1.5 percent ophthalmic solution for the treatment of meibomian gland dysfunction. Clin Exp Optom, 2018, 101(1): 18-22. DOI: 10.1111/cxo.12557.
[5]	Opitz DL, Tyler KF.Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom, 2011, 94(2): 200-206. DOI: 10.1111/j.1444-0938.2010.00540.x.
[6]	Igami TZ, Holzchuh R, Osaki TH, et al.Oral azithromycin for treatment of posterior blepharitis. Cornea, 2011, 30(10): 1145-1149. DOI: 10.1097/ICO.0b013e318207fc42.
[7]	Kashkouli MB, Fazel AJ, Kiavash V, et al. Oral azithromycin versus doxycycline in meibomian gland dysfunction: A randomised double-masked open-label clinical trial. Br J Ophthalmol, 2015, 99(2): 199-204. DOI: 10.1136/bjophthalmol- 2014-305410.
[8]	Geerling G, Tauber J, Baudouin C, et al.The international workshop on meibomian gland dysfunction: Report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci, 2011, 52(4): 2050-2064. DOI: 10.1167/iovs.10-6997g.
[9]	Tomlinson A, Bron AJ, Korb DR, et al.The international workshop on meibomian gland dysfunction: Report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci, 2011, 52(4): 2006-2049. DOI: 10.1167/iovs.10-6997f.
[10]	Fenga C, Aragona P, Di NC, et al.Comparison of ocular surface disease index and tear osmolarity as markers of ocular surface dysfunction in video terminal display workers. Am J Ophthalmol, 2014, 158(1): 41-48.e2. DOI: 10.1016/j.ajo.2014.03.007.
[11]	董雪青, 高莹莹, 赵华轩, 等. 改良和传统睑板腺压榨手法治疗睑板腺功能障碍的比较. 中国实用眼科杂志, 2015, 33(1): 72-77. DOI: 10.3760/cma.j.issn.1006-4443.2015.01.019.
[12]	刘木, 高莹莹, 赵华轩, 等. 睑板腺形态及功能与阻塞性睡眠呼吸暂停综合征的关系. 中华眼视光学与视觉科学杂志, 2017, 19(2): 111-116. DOI: 10.3760/cma.j.issn.1674-845X. 2017.02.009.
[13]	Amano S, Inoue K.Estimation of prevalence of meibomian gland dysfunction in Japan. Cornea, 2017, 36(6): 684-688. DOI: 10.1097/ICO.0000000000001208.
[14]	Li J, Zheng K, Deng Z, et al.Prevalence and risk factors of dry eye disease among a hospital-based population in southeast China. Eye Contact Lens, 2015, 41(1): 44-50. DOI: 10.1097/ICL.0000000000000064.
[15]	Lee H, Min K, Kim EK, et al. Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction. Am J Ophthalmol, 2012,154(6): 949-957.e1. DOI: 10.1016/j.ajo.2012.06.009.
[16]	Doughty MJ.On the prescribing of oral doxycycline or minocycline by UK optometrists as part of management of chronic meibomian gland dysfunction (MGD). Cont Lens Anterior Eye, 2016, 39(1): 2-8. DOI: 10.1016/j.clae.2015.08.002.
[17]	Al-Hity A, Lockington D.Oral azithromycin as the systemic treatment of choice in the treatment of meibomian gland disease. Clin Exp Ophthalmol, 2016, 44(3): 199-201. DOI: 10.1111/ceo. 12666.
[18]	Liu Y, Kam WR, Ding J, et al.Can tetracycline antibiotics duplicate the ability of azithromycin to stimulate human meibomian gland epithelial cell differentiation. Cornea, 2015, 34(3): 342-346. DOI: 10.1097/ICO.0000000000000351.
[19]	Liu Y, Ding J.The combined effect of azithromycin and insulin-like growth factor-1 on cultured human meibomian gland epithelial cells. Invest Ophthalmol Vis Sci, 2014, 55(9): 5596-5601. DOI: 10.1167/iovs.14-14782.
[20]	Liu Y, Kam WR, Ding J, et al.One man's poison is another man's meat: Using azithromycin-induced phospholipidosis to promote ocular surface health. Toxicology, 2014, 320: 1-5. DOI: 10.1016/j.tox.2014.02.014.
[21]	Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol, 1984, 68(8): 524-528. DOI: 10.1136/bjo.68.8.524.
[22]	Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci, 1986, 27(4): 486-491.
[23]	张梦丹, 李莎, 王伟, 等. 阿奇霉素潜在的致心律失常不良反应的研究状况. 中国临床药理学杂志, 2016, 32(4): 376-378. DOI: 10.13699/j.cnki.1001-6821.2016.04.031.
[24]	Zhang L, Su Z, Zhang Z, et al.Effects of azithromycin on gene expression profiles of proinflammatory and anti-inflammatory mediators in the eyelid margin and conjunctiva of patients with meibomian gland disease. JAMA Ophthalmol, 2015, 133(10): 1117-1123. DOI: 10.1001/jamaophthalmol.2015.2326.
[25]	Letterio JJ, Roberts AB.Regulation of immune responses by TGF-beta. Annu Rev Immunol, 1998, 16: 137-161. DOI: 10.1146/annurev.immunol.16.1.137.
[26]	Gupta A, Monroy D, Ji Z, et al.Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res, 1996, 15(6): 605-614.
[27]	Yoshino K, Garg R, Monroy D, et al.Production and secretion of transforming growth factor beta (TGF-beta) by the human lacrimal gland. Curr Eye Res, 1996, 15(6): 615-624.
[28]	Li MO, Wan YY, Sanjabi S, et al.Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol, 2006, 24: 99-146. DOI: 10.1146/annurev.immunol.24.021605.090737.
[29]	Bongiovanni L, Muller EJ, Della Salda L.Survivin in skin pathologies. Exp Dermatol, 2011, 20(6): 457-463. DOI: 10.1111/j.1600-0625.2011.01273.x.
[30]	Xiao YQ, Malcolm K, Worthen GS, et al.Cross-talk between erk and p38 mapk mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem, 2002, 277(17): 14884-14893. DOI: 10.1074/jbc.M111718200.
[31]	Incorvaia C, Frati F, Puccinelli P, et al.Effects of sublingual immunotherapy on allergic inflammation. Inflamm Allergy Drug Targets, 2008, 7(3): 167-172.
[32]	Wahl SM, Hunt DA, Wong HL, et al.Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol, 1988, 140(9): 3026-3032.
[33]	Tiemessen MM, Kunzmann S, Schmidt-Weber CB, et al.Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine response. Int Immunol, 2003, 15(12): 1495-1504. DOI: 10.1093/intimm/dxg147.